Belt and Road Weekly Investor Intelligence #6

Welcome to this week’s issue of China Briefing’s Belt & Road Initiative Weekly Investor Intelligence round up.

As COVID-19 vaccines start to come to market, we look at the two different types of vaccines that are being developed, their pros and cons, and where across Asia distribution will commence and when.        

Special Report: COVID-19 2021 Vaccine Distribution Across Asia

We provide details of 40 countries in Asia and their plans for domestic COVID-19 vaccination distribution.

China’s COVID-19 Vaccine Development and Availability

China’s COVID-19 vaccines are expected to be rolled out soon; bulk manufactured and exported in 2021. China could likely mass inoculate citizens in any outbreak that crosses a certain threshold; the country is expected to develop herd immunity over longer term. The Sinovac vaccine (in limited roll-out) costs RMB 400.

COVID-19 Vaccine Roll Outs in ASEAN & Asia – Live Updates by Country

Details of COVID-19 vaccine development in all 10 ASEAN countries.

India COVID-19 Vaccine Development and Availability

The Indian Government is partnering with Russian, British and domestic firms for vaccine production, with a two shot treatment to be available from January 2021. Competitive consumer pricing agreed with BRICS nations.

Russia Begins Global Ramp Up Of Covid-19 Sputnik V Vaccine

Mass vaccinations commence this month in Russia, with overseas manufacturing partnerships with other countries Sovereign Wealth Funds from January 2021. There remain production scale issues over the sheer size of populations.

• Previous Article China to Undertake Massive 10,000 km Domestic Rail Network Expansion to Link Key City Clusters
• Next Article Suzhou City Profile: Investment Stronghold and Innovation Trailblazer